When products were required under the terms of a licence to undergo a "batch release" process, manufacturers were required to submit to NIBSC protocols which described the results of in-process tests made during the manufacture and, in most cases, submit samples.
Linked evidence
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates